BridgeBio Oncology Therapeutics (BBOT) Cash & Current Investments (2024 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Cash & Current Investments of $252.3 million for Q1 2026, down 40.71% sequentially from $425.5 million in Q4 2025, and up 26093.11% YoY from N/an in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Cash & Current Investments (2024 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Cash & Current Investments for 3 years, with the latest figure at $252.3 million in Q1 2026.
- Quarterly Cash & Current Investments rose 26093.11% year-over-year to $252.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $252.3 million (up 26093.11% YoY) and the FY2025 annual result came in at $425.5 million, up 173.38% from the prior year.
- Cash & Current Investments eased to $252.3 million in Q1 2026 per BBOT's latest filing, from $425.5 million in the prior quarter.
- Over five years, Cash & Current Investments peaked at $468.3 million in Q3 2025 and troughed at $664231.0 in Q2 2025.
- A 3-year average of $145.4 million and a median of $1.8 million in 2024 frame the typical range for Cash & Current Investments.
- The widest YoY moves for Cash & Current Investments: up 26125.11% in 2025, down 63.39% in 2025.
- Over 3 years, Cash & Current Investments stood at $155.6 million in 2024, then soared by 173.38% to $425.5 million in 2025, then slumped by 40.71% to $252.3 million in 2026.
- According to Business Quant data, Cash & Current Investments over the past three periods registered $252.3 million, $425.5 million, and $468.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 836.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.16 Bn |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | 225.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 225.71 Mn |
| Mar 31, 2026 | 252.28 Mn |
| Dec 31, 2025 | 425.46 Mn |
| Sep 30, 2025 | 468.29 Mn |
| Jun 30, 2025 | 664,231.00 |
| Mar 31, 2025 | 963,135.00 |
| Dec 31, 2024 | 155.63 Mn |
| Sep 30, 2024 | 1.79 Mn |
| Jun 30, 2024 | 1.81 Mn |
| Mar 31, 2024 | 1.84 Mn |